

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): An isolated oligonucleotide as alpha-arteether resistance domain (ADR) of SEQ ID No. 1.

Claim 2 (original): An oligonucleotide as alpha-arteether resistance domain (ADR) as claimed in claim 1, wherein the domain is from 241 to 261 nucleotide position of *gyr A* gene from translation start site of *E. Coli*.

Claim 3 (withdrawn): An oligopeptide of SEQ ID No. 2, corresponding to an oligonucleotide as alpha-arteether resistance domain (ADR) of SEQ ID No. 1.

Claim 4 (withdrawn): An oligopeptide as claimed in claim 3, wherein the oligopeptide is from amino acid position 81 to 87 in *gyrase A* peptide of the enzyme.

Claim 5 (withdrawn): A method of identifying alpha-arteether resistance domain (ADR) in an alpha-arteether resistant pathogens, to help develop drugs against the pathogen, said method comprising steps of:

- a. developing alpha-arteether resistant mutant from arteether sensitive strain,
- b. identifying both phenotypic and genotypic characteristics of the developed alpha-arteether resistant mutant, and
- c. identifying alpha-arteether resistance domain (ADR) in an alpha-arteether resistant pathogens.

Claim 6 (withdrawn): A method as claimed in claim 5, wherein an alpha-arteether resistance domain (ADR) is an oligonucleotide of SEQ ID No. 1.

Claim 7 (withdrawn): A method as claimed in claim 5, wherein the ADR is from 241 to 261 nucleotide position of *gyr A* gene from translation start site of *E. Coli*.

Claim 8 (withdrawn): A method as claimed in claim 5, wherein the ADR has corresponding an oligopeptide of SEQ ID No. 2.

Claim 9 (withdrawn): A method as claimed in claim 8, wherein the oligopeptide is from amino acid position 81 to 87 in *gyrase A* peptide of the enzyme.

Claim 10 (original): A set of three pairs of primers of SEQ ID Nos. 3, 4; 5, 6; and 7, 8.

Claim 11 (original): A set of primers as claimed in claim 10, wherein the primers of SEQ ID Nos 3, 5 and 7 are forward primers.

Claim 12 (original): A set of primers as claimed in claim 10, wherein the primers of SEQ ID Nos 4, 6 and 8 are reverse primers.